Search Result

Results for "

autophagic degradation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Androgen Receptor (1) Apoptosis (1) ATTECs (3) AUTACs (1) Autophagy (10) AUTOTACs (4) Biochemical Assay Reagents (2) Caspase (1) CDK (1) E3 Ligase Ligand-Linker Conjugates (1) Enolase (1) Environmental Pollutants (1) ERK (1) FLT3 (1) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (3) mTOR (2) PCSK9 (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (2) PIKfyve (1) PROTACs (1) Reference Standards (1) RET (1) Target Protein Ligand-Linker Conjugates (1)
By Research Areas:	Cancer (18) Cardiovascular Disease (1) Inflammation/Immunology (4) Metabolic Disease (4) Neurological Disease (6)

By Targets:

AMPK (1)

Androgen Receptor (1)

Apoptosis (1)

ATTECs (3)

AUTACs (1)

Autophagy (10)

AUTOTACs (4)

Biochemical Assay Reagents (2)

Caspase (1)

CDK (1)

E3 Ligase Ligand-Linker Conjugates (1)

Enolase (1)

Environmental Pollutants (1)

ERK (1)

FLT3 (1)

Ligands for E3 Ligase (2)

Ligands for Target Protein for PROTAC (3)

mTOR (2)

PCSK9 (1)

PD-1/PD-L1 (1)

Phosphodiesterase (PDE) (2)

PIKfyve (1)

PROTACs (1)

Reference Standards (1)

RET (1)

Target Protein Ligand-Linker Conjugates (1)

By Research Areas:

Cancer (18)

Cardiovascular Disease (1)

Inflammation/Immunology (4)

Metabolic Disease (4)

Neurological Disease (6)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D0195

Acesulfame potassium	Environmental Pollutants Biochemical Assay Reagents	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Acesulfame potassium is a synthetic sweetener. Long-term use of Acesulfame potassium can affect cognitive function, possibly by altering the neurometabolic functions in mice. Acesulfame potassium can suppress autophagic degradation of PD-L1 in RIL-175 and SK-Hep1 cells through the ERK1/2-mTORC1-ULK1 pathway, which may be related to immune evasion in cancer cells. Acesulfame potassium can be used in research on neurological diseases, metabolic disorders, cancer, and immune evasion .

HY-158420

STL001	Autophagy	Cancer
STL001 is potent and selective FOXM1 inhibitor. STL001 induces the translocation of nuclear FOXM1 to the cytoplasm and promotes its *autophagic* degradation. STL001 sensitizes human cancers to a broad-spectrum of cancer therapies .

HY-161743

PBA-1105	AUTOTACs Autophagy	Neurological Disease Cancer
PBA-1105 is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1105 selectively binds to exposed hydrophobic regions of misfolded proteins, facilitating their degradation via the autophagic pathway. PBA-1105 increases the autophagic flux of Ub-conjugated aggregates .

HY-161746

Anle138b-F105	AUTOTACs Autophagy	Neurological Disease
Anle138b-F105 is an autophagy-targeting chimera (AUTOTAC) that targets p62/Sequestosome-1/SQSTM1. Anle138b-F105 binds to the ZZ domain of p62, induces conformational activation, self-oligomerization, interaction with LC3, and formation of autophagosomes. Anle138b-F105 induces autophagic flux of ubiquitin-conjugated aggregated proteins, leading to their lysosomal degradation. Anle138b-F105 is applicable for the research of neurodegenerative proteinopathies .

HY-155994

PIK5-12d 1 Publications Verification	PROTACs PIKfyve Autophagy	Cancer
PIK5-12d is a PROTAC PIKfyve degrader (DC₅₀ = 1.48 nM). PIK5-12d induces massive cytoplasmic vacuolization and blocks autophagic flux in multiple prostate cancer cells. PIK5-12d inhibits prostate cancer cell proliferation. PIK5-12d significantly suppresses tumor proliferation in mice bearing LTL-331R human prostate cancer PDX tumors. PIK5-12d can be used for the study of prostate cancer. (Pink: PIKfyve ligand (HY-175631), Blue: VHL Ligand (HY-125845), Black: Linker, PIKfyve ligand-linker conjugate (HY-175632)) .

HY-155971

VISTA-IN-2	Autophagy	Inflammation/Immunology Cancer
VISTA-IN-2 (Compound 1) is an inhibitor of V-domain Ig suppressor of T-cell activation (VISTA). VISTA-IN-2 induces VISTA degradation in cells through an autophagic mechanism. VISTA-IN-2 rescues VISTA-mediated immunosuppression, and enhances antitumor activity of immune cells. VISTA-IN-2 also activates the antitumor immunity and inhibits tumor growth in a CT26 mouse model .

HY-175689

PDEδ-IN-1	Ligands for Target Protein for PROTAC Phosphodiesterase (PDE)	Cancer
PDEδ-IN-1 is the ligand of PDEδ. PDEδ-IN-1 can be used to synthesize PDEδ autophagic degrader 1 (HY-157458) .

HY-157458

PDEδ autophagic degrader 1	ATTECs Phosphodiesterase (PDE) Autophagy	Cancer
PDEδ autophagic degrader 1 (compound 12c), an autophagosome-tethering compound (ATTEC). is a potent PDEδ autophagic degrader. PDEδ autophagic degrader 1 reduces the PDEδ protein level through lysosome-mediated autophagy without affecting the PDEδ mRNA expression. PDEδ autophagic degrader 1 suppresses the growth in KRAS mutant pancreatic cancer cells .

HY-160902

2G-HaloAUTAC	Autophagy AUTACs	Others
2G-HaloAUTAC (Compound tt44) is a Autophagy-targeting chimera (2G-HaloAUTAC) that improves the activity of AUTACs by replacing the L-Cysteine (L-Cys) linker with other structures. 2G-HaloAUTAC exhibits degradation activity against EGFP-HaloTag protein through an *Autophagic* mechanism .

HY-175665

LC3 liagnd-2	Ligands for E3 Ligase	Others
LC3 liagnd-2 is an E3 ligase ligand. LC3 liagnd-2 can be used for synthesis of PROTAC PDEδ autophagic degrader 1 (HY-157458) .

HY-179578

SU212	Enolase AMPK Autophagy Apoptosis mTOR Caspase	Metabolic Disease Cancer
SU212 is a podophyllotoxin-derived ENO1 inhibitor and AMPK activator. SU212 can selectively induce oxidative phosphorylation, reduce glycolysis activity and glucose uptake in tumor cells, and directly bind to ENO1 without affecting these pathways in normal cells. SU212 induces apoptosis and promotes ENO1 degradation via proteasomal and *autophagic* pathways without inhibiting the catalytic activity. SU212 leads to mitotic arrest and apoptosis in TNBC (triple-negative breast cancer) cells by activating AMPK, demonstrating potent anti-tumor activity in vitro. SU212 inhibits tumor growth and metastasis in syngeneic, xenograft, and diabetic mouse models, exhibiting an excellent safety profile. SU212 can be used in research on t TNBC, diabetes, and fatty liver disease .

HY-168896

CDK9 autophagic degrader 1	CDK ATTECs	Cancer
CDK9 autophagic degrader 1 (Compound 28) is a ATTEC degrader that can be used to degrade CDK9 and also affects the levels of the associated Cyclin T1. CDK9 autophagic degrader 1 shows over 80% CDK9 inhibition rate at 100 nM . ( Pink: LC3B ligand (HY-168897); Black: linker (HY-W017758); Blue: target protein ligand (HY-10008); linker + target protein ligand (HY-168898))

HY-176043

PCSK9 autophagic degrader 2	ATTECs PCSK9	Cancer
PCSK9 autophagic degrader 2 (W6) is a PCSK9 targeted autophagosome, with an DC₅₀ of 20.6 nM. PCSK9 autophagic degrader 2 (W6) demonstrates comparable antiatherosclerosis effect and exhibits a K_D of 2.5 μM for LC3B (Pink: PCSK9 ligand HY-176044; Blue: LC3B ligand HY-176045; Black: linker HY-141373) .

HY-176045

LC3B ligand 2	Ligands for E3 Ligase	Cardiovascular Disease Cancer
LC3B ligand 2 is a ligand for E3 ubiquitin ligase. LC3B ligand 2 can be connected to the ligand for protein by a linker to form PROTAC PCSK9 autophagic degrader 2 (HY-176043). PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-149539

PLM-101	FLT3 RET	Cancer
PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po) .

HY-161743A

PBA-1105 TFA	AUTOTACs Autophagy	Neurological Disease Cancer
PBA-1105 TFA is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1105 TFA selectively binds to exposed hydrophobic regions of misfolded proteins, facilitating their degradation via the autophagic pathway. PBA-1105 TFA increases the autophagic flux of Ub-conjugated aggregates .

HY-176044

PCSK9 ligand 2	Ligands for Target Protein for PROTAC	Cancer
PCSK9 ligand 2 is a target protein ligand for PROTAC PCSK9 autophagic degrader 2 (HY-176043), which can be used in antiatherosclerosis research .

HY-168897

LC3B ligand 1	Ligands for Target Protein for PROTAC	Others
LC3B ligand 1 is a ligand for the target protein of PROTAC and can be used for the synthesis of PROTAC CDK9 autophagic degrader 1 (HY-168896) .

HY-168898

1,3-Propanediol-SNS-032	Target Protein Ligand-Linker Conjugates	Others
1,3-Propanediol-SNS-032 is a target protein ligand and linker conjugate, which can be used for the synthesis of PROTAC CDK9 autophagic degrader 1 (HY-168896) .

HY-161741

VinclozolinM2-2204	AUTOTACs Androgen Receptor	Cancer
VinclozolinM2-2204 is a androgen receptor (AR) AUTOTAC degrader, with an DC₅₀ of 200 nM in LNCaP prostate cancer cells. VinclozolinM2-2204 induces the formation of AR ⁺LC3 ⁺ autophagic membranes. VinclozolinM2-2204 can be used for the research of cancer .(Pink: AR inhibitor (HY-168296); Black: linker (HY-128833); Blue: CRBN Ligand (HY-168293))

HY-W550739

Acesulfame	PD-1/PD-L1 ERK mTOR Autophagy	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Acesulfame is a synthetic sweetener. Long-term use of Acesulfame can affect cognitive function. Acesulfame potassium can suppress autophagic degradation of PD-L1 in RIL-175 and SK-Hep1 cells through the ERK1/2-mTORC1-ULK1 pathway, which may be related to immune evasion in cancer cells. Acesulfame can be used in research on neurological diseases, metabolic disorders, cancer, and immune evasion .

HY-D0195R

Acesulfame potassium (Standard)	Biochemical Assay Reagents Reference Standards	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Acesulfame potassium (Standard) is the analytical standard of Acesulfame potassium (HY-D0195). This product is intended for research and analytical applications. Acesulfame potassium is a synthetic sweetener. Long-term use of Acesulfame potassium can affect cognitive function, possibly by altering the neurometabolic functions in mice. Acesulfame potassium can suppress autophagic degradation of PD-L1 in RIL-175 and SK-Hep1 cells through the ERK1/2-mTORC1-ULK1 pathway, which may be related to immune evasion in cancer cells. Acesulfame potassium can be used in research on neurological diseases, metabolic disorders, cancer, and immune evasion .

HY-176046

E3 Ligase Ligand-linker Conjugate 183	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 183 is an E3 ligase ligand-linker conjugate of PCSK9 autophagic degrader 2 (HY-176043). E3 Ligase Ligand-linker Conjugate 183 consists of LC3B ligand 2 (HY-176045) and the corresponding linker (HY-141373) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

autophagic degradation

Inhibitors & Agonists